BioCentury
ARTICLE | Clinical News

Rhône-Poulenc Rorer Inc. regulatory update

July 17, 1995 7:00 AM UTC

RPR filed for Canadian marketing approval of Rilutek (riluzole) to treat amyotrophic lateral sclerosis (ALS). The Collegeville, Penn., company has filed for marketing approval of the drug in both Eur...